CDMO– tag –
-
AGC Biologics Secures Multi-Million Dollar Commercial Manufacturing Deal for Yokohama Facility Ahead of 2027 Opening
히트뉴스 (HITNews) South Korea Overview AGC Biologics has signed a multi-year commercial manufacturing contract with an undisclosed global biopharmaceutical company for its new Yokohama facility, reserving approximately half of its mamma... -
Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout
Samsung Biologics South Korea Overview Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide G... -
PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities
BioSpace USA Overview This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs' $2.... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Ultragenyx’s Genglycos Receives FDA Accelerated Approval as First Gene Therapy for Glycogen Storage Disease Type Ia, Requiring 10-Year Post-Marketing Monitoring
Pharmaceutical Technology USA Overview Ultragenyx Pharmaceutical announced that Genglycos (pariglasgene brecaparvovec-opnr), the first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), has received FDA accelerated approval. This... -
Bioseon Unveils Proof-Driven Operating Guides for Autonomous Biologics Manufacturing, Supporting CDMOs and Biopharma with Live Titer & CQA Control via Soft Sensors and Digital Twins
Bioseon Unknown Overview Bioseon has released 'Proof-Driven Operating Guides' for autonomous biologics manufacturing. These guides focus on live titer and critical quality attribute (CQA) control utilizing soft sensors, Process Analytica... -
PackGene Biotech’s π-alpha 293 Platform Achieves 10x AAV Production Amplification, Up to 1e+17vg/Batch, Supporting Remedium Bio’s Gene Therapy Advancement
PackGene Biotech China Overview PackGene Biotech announced its innovative π-alpha 293 AAV high-yield platform, capable of amplifying adeno-associated virus (AAV) production up to 10-fold and achieving an impressive yield of up to 1e+17vg... -
Viral Vector Manufacturing: Global Leaders Scale Up Capacity with Advanced Platforms and Strategic Acquisitions
The Business Research Company International Overview The viral vector manufacturing market is experiencing rapid expansion as major players intensify efforts to scale production for gene therapies and vaccines. Recent strategic moves inc... -
Early Manufacturing Planning Critical for Commercial Success of Advanced Therapies: Ensuring Scalability from Process Design to Automation
The Medicine Maker International Overview The commercial success of advanced therapies heavily depends on meticulous manufacturing planning from the early development stages. Sponsors must assess process consistency, effective technology... -
NueCell Bio Unveils 26,300 Sq Ft Cell Therapy Development Facility in San Diego, Bolstering Clinical & Commercial Manufacturing
PharmaSource USA Overview NueCell Bio has officially opened its 26,300-square-foot cell therapy development facility in San Diego, significantly enhancing its clinical and commercial manufacturing capabilities. The state-of-the-art facil...
